Cost-effectiveness of 12 months of capecitabine as adjuvant chemotherapy for stage III colon cancer: preplanned cost-effectiveness analysis of the JFMC37-0801 study

OBJECTIVES: We evaluated the cost-effectiveness of a 12-month regimen of oral capecitabine versus a standard 6-month regimen as postoperative adjuvant chemotherapy for stage III colon cancer. METHODS: We utilized patient-level data from a multi-institutional randomized controlled trial (JFMC37-0801)...

Descripción completa

Detalles Bibliográficos
Autores principales: Shibahara, Hidetoshi, Shiroiwa, Takeru, Ishiguro, Megumi, Nakamura, Masato, Hasegawa, Junichi, Yamaguchi, Shigeki, Masuda, Yuriko, Sakamoto, Junichi, Tomita, Naohiro, Fukuda, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395498/
https://www.ncbi.nlm.nih.gov/pubmed/35072852
http://dx.doi.org/10.1007/s10198-021-01418-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395498/
https://www.ncbi.nlm.nih.gov/pubmed/35072852
http://dx.doi.org/10.1007/s10198-021-01418-6

Ejemplares similares